Cargando…

A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal heterogeneous disease with a varied clinical course that is difficult to predict. Accurate predictive models are urgently needed to identify individuals with poor survival for the optimal timing of referral for transplantation and provide so...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Ziliang, Peng, Dan, Yang, Jingjing, Zhang, Shuai, Wang, Jinxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186233/
https://www.ncbi.nlm.nih.gov/pubmed/35693599
http://dx.doi.org/10.21037/jtd-21-1830
_version_ 1784724886518759424
author Hou, Ziliang
Peng, Dan
Yang, Jingjing
Zhang, Shuai
Wang, Jinxiang
author_facet Hou, Ziliang
Peng, Dan
Yang, Jingjing
Zhang, Shuai
Wang, Jinxiang
author_sort Hou, Ziliang
collection PubMed
description BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal heterogeneous disease with a varied clinical course that is difficult to predict. Accurate predictive models are urgently needed to identify individuals with poor survival for the optimal timing of referral for transplantation and provide some clues for mechanistic research on disease progression. METHODS: We obtained the gene expression profiles of bronchoalveolar lavage fluid (BALF) from the Gene Expression Omnibus. Individuals from the GPL14550 platform were assigned to the derivation cohort (n=112) and individuals from the GPL17077 platform to the validation cohort (n=64). Univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were applied to select candidate genes for overall survival. A nomogram model was constructed based on Cox hazard regression analysis. The model was assessed by C-statistic, calibration curve, and decision curve analysis (DCA) and was externally validated. RESULTS: A nomogram model comprising seven genes was constructed. Excellent discrimination and calibration were observed in the derivation (C-index 0.815) and validation (C-index 0.812) cohorts. The AUCs for predicting 1-, 2- and 3-year survival were 0.857, 0.918, 0.930 in the derivation cohort and 0.850, 0.880, 0.925 in the validation cohort, respectively. DCA confirmed the clinical applicability of the model. A risk score based on the model was an independent prognostic predictor and could divide patients into high- and low-risk groups. The Kaplan-Meier analysis displayed that high-risk patients exhibited significantly poorer survival compared with low-risk patients. Gene Set Enrichment Analysis (GSEA) showed that high-risk patients were primarily enriched in inflammatory hallmarks, and single sample GSEA (ssGSEA) indicated that the high-risk group is closely correlated with the immune process. These lead to increased insight into mechanisms associated with IPF progression that inflammation mediated by immune response might be involved in the disease progression. CONCLUSIONS: The novel BALF seven-gene model performed well in risk stratification and individualized survival prediction for patients with IPF, facilitating personalized management of IPF patients. It deepened the understanding of the role of inflammation in IPF progression, which needs to be further studied.
format Online
Article
Text
id pubmed-9186233
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-91862332022-06-11 A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis Hou, Ziliang Peng, Dan Yang, Jingjing Zhang, Shuai Wang, Jinxiang J Thorac Dis Original Article BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal heterogeneous disease with a varied clinical course that is difficult to predict. Accurate predictive models are urgently needed to identify individuals with poor survival for the optimal timing of referral for transplantation and provide some clues for mechanistic research on disease progression. METHODS: We obtained the gene expression profiles of bronchoalveolar lavage fluid (BALF) from the Gene Expression Omnibus. Individuals from the GPL14550 platform were assigned to the derivation cohort (n=112) and individuals from the GPL17077 platform to the validation cohort (n=64). Univariate Cox and least absolute shrinkage and selection operator (LASSO) regression analyses were applied to select candidate genes for overall survival. A nomogram model was constructed based on Cox hazard regression analysis. The model was assessed by C-statistic, calibration curve, and decision curve analysis (DCA) and was externally validated. RESULTS: A nomogram model comprising seven genes was constructed. Excellent discrimination and calibration were observed in the derivation (C-index 0.815) and validation (C-index 0.812) cohorts. The AUCs for predicting 1-, 2- and 3-year survival were 0.857, 0.918, 0.930 in the derivation cohort and 0.850, 0.880, 0.925 in the validation cohort, respectively. DCA confirmed the clinical applicability of the model. A risk score based on the model was an independent prognostic predictor and could divide patients into high- and low-risk groups. The Kaplan-Meier analysis displayed that high-risk patients exhibited significantly poorer survival compared with low-risk patients. Gene Set Enrichment Analysis (GSEA) showed that high-risk patients were primarily enriched in inflammatory hallmarks, and single sample GSEA (ssGSEA) indicated that the high-risk group is closely correlated with the immune process. These lead to increased insight into mechanisms associated with IPF progression that inflammation mediated by immune response might be involved in the disease progression. CONCLUSIONS: The novel BALF seven-gene model performed well in risk stratification and individualized survival prediction for patients with IPF, facilitating personalized management of IPF patients. It deepened the understanding of the role of inflammation in IPF progression, which needs to be further studied. AME Publishing Company 2022-05 /pmc/articles/PMC9186233/ /pubmed/35693599 http://dx.doi.org/10.21037/jtd-21-1830 Text en 2022 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Hou, Ziliang
Peng, Dan
Yang, Jingjing
Zhang, Shuai
Wang, Jinxiang
A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title_full A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title_fullStr A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title_full_unstemmed A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title_short A novel seven-gene risk profile in BALF to identify high-risk patients with idiopathic pulmonary fibrosis
title_sort novel seven-gene risk profile in balf to identify high-risk patients with idiopathic pulmonary fibrosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186233/
https://www.ncbi.nlm.nih.gov/pubmed/35693599
http://dx.doi.org/10.21037/jtd-21-1830
work_keys_str_mv AT houziliang anovelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT pengdan anovelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT yangjingjing anovelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT zhangshuai anovelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT wangjinxiang anovelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT houziliang novelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT pengdan novelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT yangjingjing novelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT zhangshuai novelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis
AT wangjinxiang novelsevengeneriskprofileinbalftoidentifyhighriskpatientswithidiopathicpulmonaryfibrosis